BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo SH, Chu JG, Huang H, Yao KC. Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma. World J Clin Cases 2019; 7(13): 1599-1610 [PMID: 31367619 DOI: 10.12998/wjcc.v7.i13.1599] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yan H, Qiu Z, Xiang Z, Feng K, Huang M, Gao F. TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience. Cancer Imaging 2022;22. [DOI: 10.1186/s40644-022-00451-9] [Reference Citation Analysis]
2 Lu HL, Xuan FF, Luo YC, Qin X. Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt. Abdom Radiol (NY) 2021;46:5417-27. [PMID: 34302511 DOI: 10.1007/s00261-021-03214-5] [Reference Citation Analysis]
3 Chen X, Qiu ZK, Wang GB, Chen XL, Zhang FJ, Gao F. Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Diagn Interv Radiol 2021;27:671-6. [PMID: 34318755 DOI: 10.5152/dir.2021.20358] [Reference Citation Analysis]
4 Yan H, Wang G, Zhu W, Feng K, Zhu W, Wu X, Qiu Z, Chen G, Jiang W, Zhang F, Gao F. Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites. Transl Oncol 2020;13:100864. [PMID: 32950928 DOI: 10.1016/j.tranon.2020.100864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]